US 11,780,827 B2
Substituted 3-phenoxyazetidin-1-yl-pyrazines
Kai Gerlach, Ingelheim am Rhein (DE); Graeme Semple, San Diego, CA (US); Yifeng Xiong, San Diego, CA (US); Barbara Bertani, Ingelheim am Rhein (DE); Marco Ferrara, Ingelheim am Rhein (DE); Giacomo Fossati, Ingelheim am Rhein (DE); Scott Hobson, Ingelheim am Rhein (DE); Uta Friederike Lessel, Ingelheim am Rhein (DE); Frank Runge, Ingelheim am Rhein (DE); Ursula Mueller-Vieira, Ingelheim am Rhein (DE); and Julian Wippich, Ingelheim am Rhein (DE)
Assigned to Boehringer Ingelheim International GmbH, Ingelheim am Rhein (DE); and Arena Pharmaceuticals, Inc., San Diego, CA (US)
Filed by Boehringer Ingelheim International GmbH, Ingelheim am Rhein (DE); and Arena Pharmaceuticals, Inc.
Filed on Mar. 29, 2021, as Appl. No. 17/215,759.
Claims priority of provisional application 63/001,640, filed on Mar. 30, 2020.
Prior Publication US 2022/0356172 A1, Nov. 10, 2022
Int. Cl. C07D 403/14 (2006.01)
CPC C07D 403/14 (2013.01) 11 Claims
 
1. A compound of formula (I)

OG Complex Work Unit Chemistry
wherein
A is selected from the group Aa consisting of

OG Complex Work Unit Chemistry
R is selected from the group R1a consisting of H— and F—;
R2 is selected from the group R2a consisting of H— and F—;
R3 is selected from the group R3a consisting of halogen, F2HCO—, F3CO—, F2HC— and F3C—;
R4 is selected from the group R4a consisting of
H— and C1-3-alkyl-,
wherein the above mentioned C1-3-alkyl-group may optionally be substituted with 1 to 5 substituents independently selected from the group consisting of fluorine;
or a salt thereof.